BPC-157
BC20
Lyophilized peptide for use under a licensed healthcare provider. Choose single ampule/vial or box of 10. Sourced via Ares Technology Limited (Hong Kong) / Healthtide Biotech manufacturing list dated 7 October 2026. Specification: 20 mg × 10 vials.
- • Prescription / clinician-supervised pathway
- • Same LIRAVEXIN cart and checkout as pen packages
- • Not medical advice — individual suitability is determined by your clinician
Clinical reference (clinician-supervised)
Preclinical literature explores angiogenesis, tendon/ligament healing, and gut mucosal protection. Human evidence consists of limited exploratory reports and early pilots; it is not an accepted standard-of-care orthopedic or GI drug. Cleveland Clinic and similar clinical education sources emphasize the lack of robust approved human dosing. LIRAVEXIN lists BPC-157 only under clinician-supervised framing—patients should understand investigational status and alternatives with stronger evidence when available.
No FDA-approved dose. Published human exploratory exposures have used heterogeneous routes/doses (e.g., local injections of low-mg amounts, or other experimental regimens). Common compounding-clinic anecdotes (e.g., ~250–500 mcg SC daily) are not validated standards—state clearly: clinician decides; no established human dosing.
Not established; clinic protocols vary (often daily SC in anecdotes).
Discussed as SC, IM, local, or oral in non-standardized settings.
Typical clinical / literature ranges under clinician supervision — not a prescription and not a DIY dosing guide. Individual dosing is determined solely by the treating clinician.
Liravexin USD for this pack (wholesale comparison · source × 3). Item is added to your shared cart for checkout coordination with your clinician pathway.
Or continue to checkout →